Logomix
Founded 2006 · 12 employees on LinkedIn · 10 known investors
Find your way into Logomix
488 people in our graph share verified history with the Logomix team — schools, employers, funds. One of them is your warm intro.
Genome engineering-based drug discovery and biomanufacturing R&D support.
Also known as Logomix, Inc.
Founders & leadership
Logomix was founded in 2006 by Taiki Ishikura.
Investors · 10
.png){kind=logo}
Also in the syndicate · 4
Company profile
researched Aug 2026Logomix, Inc. is a Tokyo-based mammalian synthetic biology company developing artificial human cells for new therapeutics using its Geno-Writing genome engineering platform. The platform is designed to write large-scale and complex sequences into the human genome, enabling megabase-scale genomic modification within human cells rather than point edits.
The company applies the platform to create versions of engineered human cells intended for drug discovery, cell therapy, regenerative medicine and anti-aging applications. It positions the technology as an enabler for therapy developers seeking to write therapeutic sequences for new modalities addressing cancer, neurodegenerative diseases and genetic diseases, and states the intention to pursue discovery collaborations with biopharma companies. Logomix is listed under the Medical Engineering & Biotechnology category of Japan's J-Startup program.
Business model
Logomix develops a proprietary genome engineering platform and states it intends to validate and apply the technology through partnerships and discovery collaborations with biotech and pharmaceutical companies, alongside developing its own portfolio of engineered human cells.
Latest developments
In February 2023 Logomix announced an oversubscribed $3.9 million seed round led by Angel Bridge, with proceeds directed toward building out the Geno-Writing platform, validating the technology through biotech and pharma partnerships, and establishing US-based automation capabilities for cell engineering.
▸Full profile — market position, technology, go-to-market, geography
Market position
Logomix operates in the synthetic biology and cell and gene therapy tools market, where investors in its seed round noted the emergence of world-class synthetic biology startups, primarily in the United States. It is included in Japan's government-backed J-Startup list.
Investor commentary at the time of the seed round cited the ability of Logomix's core technology to edit the genome extensively rather than at a single point, together with the founding team's combination of industry knowledge and synthetic biology technical capability.
Technology
Geno-Writing is Logomix's genome engineering platform for writing large-scale and complex sequences into a genome. It enables precise engineering of megabase-scale genomic sequences within human cells, allowing extensive genome modification rather than single-point editing, and is used to produce super-functionalized or artificial human cells.
Go-to-market
Biotech and pharmaceutical companies engaged in drug discovery and in the cell and gene therapy field, as well as developers of cell therapy and regenerative medicine products.
Geography
Headquartered in Tokyo, Japan. The company stated plans to establish automation capabilities for cell engineering and operations in the United States, where it was recruiting senior and junior scientists.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 5
by search overlap
Companies competing with Logomix for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsLogomix, Inc. is listed in the Japanese government's J-Startup program under the Medical Engineering & Biotechnology category.
Logomix, Inc. announced it raised $3.9 million in an oversubscribed seed financing led by Angel Bridge with participation from JAFCO, Tokyo IPC, Sand Hill Angels and Yasunori Kaneko, former Managing Director at Skyline Ventures. Funds are to be used to build out the Geno-Writing platform, validate the technology through biotech and pharma partnerships, and establish cell engineering automation and operations in the United States.
$3.9M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Logomix Inc. Raises $3.9M USD in Oversubscribed Seed Funding Round to Accelerate Its Platform and Portfolio Development. - BioSpacebiospace.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Logomix do?
- Tokyo-based synthetic biology company building the Geno-Writing genome engineering platform for engineered human cells.
- Who founded Logomix?
- Logomix was founded by Taiki Ishikura in 2006.
- Who are Logomix's investors?
- Logomix's investors include Angel Bridge Co.,Ltd., Aozora Corporate Investment, Delight Ventures, Globis Capital Partners, MIRAI SOUZOU, UTokyo Innovation Platform Co. Ltd..